June 30, 2026 · Form 4 insider transaction
Fenton Mary Kay bought 1,541 shares of Cullinan Therapeutics, Inc. at $8.60 per share, a transaction worth $13.3K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).; In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026.